I’ll never understand how a study like this gets through peer review. While GLP-1RA & SGLT2i meds are pretty amazing, they can’t decrease risk for dementia the moment you get a prescription. That’s a clear signal that the groups are different at baseline. #medsky
https://jamanetwork.com/journals/jamaneurology/article-abstract/2831976